Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 542.20
-6.90 (-1.26%)
At close: Dec 5, 2025
Cohance Lifesciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2019 - 2020 |
Net Income | 1,770 | 2,679 | 3,003 | 4,113 | 4,538 | 3,623 | Upgrade |
Depreciation & Amortization | 995.9 | 774.9 | 546 | 464.6 | 390.22 | 316.89 | Upgrade |
Other Amortization | - | - | - | - | 3.91 | 3.85 | Upgrade |
Loss (Gain) From Sale of Assets | -65 | 1.1 | 0.7 | 0.07 | -0.01 | -0.34 | Upgrade |
Loss (Gain) From Sale of Investments | -383 | -400.3 | -449.1 | -156.87 | -82.03 | -33.28 | Upgrade |
Stock-Based Compensation | 70.9 | 149.2 | 19.7 | - | - | - | Upgrade |
Other Operating Activities | -178.2 | -0.6 | 8.5 | 93.58 | 389.52 | 36.65 | Upgrade |
Change in Accounts Receivable | -61.8 | -1,480 | 128.2 | 1,245 | -1,361 | 133.61 | Upgrade |
Change in Inventory | -669.6 | 741.2 | 816.1 | -293.93 | -823.37 | -262.08 | Upgrade |
Change in Accounts Payable | 503.4 | 417 | -225.2 | -357.99 | 232.04 | 119.45 | Upgrade |
Change in Other Net Operating Assets | 94.5 | - | - | -535.05 | 12.55 | -112.71 | Upgrade |
Operating Cash Flow | 2,077 | 2,882 | 3,848 | 4,572 | 3,300 | 3,825 | Upgrade |
Operating Cash Flow Growth | -26.83% | -25.11% | -15.84% | 38.54% | -13.74% | -5.99% | Upgrade |
Capital Expenditures | -711.1 | -1,557 | -518.8 | -2,859 | -751.87 | -1,108 | Upgrade |
Sale of Property, Plant & Equipment | - | - | - | 0.72 | 0.01 | 0.34 | Upgrade |
Cash Acquisitions | -4,714 | -7,280 | - | - | - | - | Upgrade |
Investment in Securities | 3,403 | 6,234 | -3,101 | 844.55 | -560.72 | -2,005 | Upgrade |
Other Investing Activities | -271.1 | 50.1 | -4.2 | 63.79 | -49.49 | -0.54 | Upgrade |
Investing Cash Flow | -2,293 | -2,553 | -3,624 | -1,950 | -1,362 | -3,114 | Upgrade |
Short-Term Debt Issued | - | 246.4 | - | - | - | 123.02 | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 8.91 | Upgrade |
Total Debt Issued | 192.2 | 246.4 | - | - | - | 131.93 | Upgrade |
Short-Term Debt Repaid | - | - | -270.4 | -26.11 | -385.97 | - | Upgrade |
Long-Term Debt Repaid | - | -108.9 | -60 | -241.33 | -98.51 | -547.27 | Upgrade |
Total Debt Repaid | 1,395 | -108.9 | -330.4 | -267.43 | -484.48 | -547.27 | Upgrade |
Net Debt Issued (Repaid) | 1,588 | 137.5 | -330.4 | -267.43 | -484.48 | -415.34 | Upgrade |
Common Dividends Paid | - | - | - | -2,037 | -509.13 | -254.57 | Upgrade |
Other Financing Activities | -539.5 | -104.3 | -69.5 | -115.56 | -61.38 | -86.72 | Upgrade |
Financing Cash Flow | 1,372 | 33.2 | -399.9 | -2,420 | -1,564 | -756.62 | Upgrade |
Foreign Exchange Rate Adjustments | 36.9 | 19.9 | - | - | 0 | 0 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | - | - | -0 | 0 | Upgrade |
Net Cash Flow | 1,193 | 381.7 | -175.7 | 202.39 | 373.82 | -45.13 | Upgrade |
Free Cash Flow | 1,366 | 1,325 | 3,329 | 1,713 | 2,548 | 2,717 | Upgrade |
Free Cash Flow Growth | -27.52% | -60.21% | 94.35% | -32.78% | -6.21% | -10.58% | Upgrade |
Free Cash Flow Margin | 11.28% | 11.06% | 31.66% | 12.78% | 19.30% | 26.91% | Upgrade |
Free Cash Flow Per Share | 5.33 | 5.18 | 13.08 | 6.73 | 10.01 | 10.67 | Upgrade |
Cash Interest Paid | 39.5 | 104.3 | 69.5 | 115.56 | 62.31 | 89.24 | Upgrade |
Cash Income Tax Paid | 621.4 | 834.4 | 1,100 | 1,458 | 1,843 | 1,094 | Upgrade |
Levered Free Cash Flow | -5,433 | 1,429 | 2,967 | 1,079 | 1,027 | 1,511 | Upgrade |
Unlevered Free Cash Flow | -5,361 | 1,506 | 3,014 | 1,159 | 1,066 | 1,568 | Upgrade |
Change in Working Capital | -133.5 | -321.4 | 719.1 | 57.68 | -1,940 | -121.73 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.